Publications by authors named "P J Duggan"
In the evaluation of a patient's primary hematologic malignancy, positron emission tomography/computed tomography (PET/CT) imaging may incidentally detect a concerning abnormality suggestive of a second concurrent cancer. Despite accounting for nearly 10% of all cancers diagnosed in Canada, there has yet to be a systematic review focused on the prevalence and significance of these incidental PET/CT findings in the context of primary hematologic malignancies. As such, a systematic search strategy was employed on MEDLINE and Embase to document the prevalence and clinical significance of incidental PET/CT findings suggestive of a second concurrent cancer detected in patients evaluated for their primary hematologic malignancy.
View Article and Find Full Text PDFBackground: Thiotepa-based autologous stem cell transplantation (ASCT) improves survival in primary central nervous system lymphoma (PCNSL), but > 30% of patients are unable to undergo ASCT following commonly used intensive induction regimens.
Methods: This retrospective population-based study included consecutive patients ≥ 18 years old with PCNSL who were intended for ASCT in Alberta, Canada between 2011 and 2022. A reduced-intensity induction protocol was further abbreviated in 2018 to decrease toxicity and expediate ASCT by incorporating rituximab, procarbazine, and only 2 doses of high-dose methotrexate and 1 cycle of high-dose cytarabine before consolidation with thiotepa-busulfan conditioning.
Article Synopsis
- Pre-clinical studies indicated that adding doxycycline to treatments could benefit patients with AL amyloidosis, but a recent trial found no improvement in progression-free survival when doxycycline was added to the CyBorD regimen.
- This study aimed to investigate the effectiveness of doxycycline alongside bortezomib-containing regimens (BCRs) in newly diagnosed AL amyloidosis patients, particularly those with cardiac issues, compared to patients receiving BCR alone.
- The results showed that there was no significant difference in treatment outcomes, such as overall response rates and time to response, between the groups receiving BCR alone and those receiving BCR with doxycycline (BCR-D).
Neuropathic pain is a type of chronic pain, usually caused by nerve damage, that responds poorly to traditional pain therapies. The N-type calcium channel (Ca2.2) is a well-validated pharmacological target to treat this condition.
View Article and Find Full Text PDF